Related Experiment Video
Updated: Jun 9, 2025

Rapid Detection of Neurodevelopmental Phenotypes in Human Neural Precursor Cells NPCs
Published on: March 2, 2018
SPROUTY2, a Negative Feedback Regulator of Receptor Tyrosine Kinase Signaling, Associated with Neurodevelopmental
Nidhi Puranik1, HoJeong Jung1, Minseok Song1
1Department of Life Sciences, Yeungnam University, Gyeongsan 38541, Republic of Korea.
Abstract:
Growth-factor-induced cell signaling plays a crucial role in development; however, negative regulation of this signaling pathway is important for sustaining homeostasis and preventing diseases. SPROUTY2 (SPRY2) is a potent negative regulator of receptor tyrosine kinase (RTK) signaling that binds to GRB2 during RTK activation and inhibits the GRB2-SOS complex, which inhibits RAS activation and attenuates the downstream RAS/ERK signaling cascade. SPRY was formerly discovered in Drosophila but was later discovered in higher eukaryotes and was found to be connected to many developmental abnormalities. In several experimental scenarios, increased SPRY2 protein levels have been observed to be involved in both peripheral and central nervous system neuronal regeneration and degeneration. SPRY2 is a desirable pharmaceutical target for improving intracellular signaling activity, particularly in the RAS/ERK pathway, in targeted cells because of its increased expression under pathological conditions. However, the role of SPRY2 in brain-derived neurotrophic factor (BDNF) signaling, a major signaling pathway involved in nervous system development, has not been well studied yet. Recent research using a variety of small-animal models suggests that SPRY2 has substantial therapeutic promise for treating a range of neurological conditions. This is explained by its function as an intracellular ERK signaling pathway inhibitor, which is connected to a variety of neuronal activities. By modifying this route, SPRY2 may open the door to novel therapeutic approaches for these difficult-to-treat illnesses. This review integrates an in-depth analysis of the structure of SPRY2, the role of its major interactive partners in RTK signaling cascades, and their possible mechanisms of action. Furthermore, this review highlights the possible role of SPRY2 in neurodevelopmental disorders, as well as its future therapeutic implications.
Insights
SPROUTY2 (SPRY2) negatively regulates receptor tyrosine kinase (RTK) signaling, impacting neuronal development and disease. Targeting SPRY2 offers therapeutic potential for neurological conditions by modulating the RAS/ERK pathway.
Area of Science:
- Cellular and Molecular Biology
- Neuroscience
- Developmental Biology
Background:
- Growth factor signaling is vital for development but requires negative regulation for homeostasis.
- SPROUTY2 (SPRY2) is a key negative regulator of receptor tyrosine kinase (RTK) signaling, inhibiting RAS/ERK cascades.
- Dysregulation of SPRY2 is implicated in developmental abnormalities and neuronal regeneration/degeneration.
Purpose of the Study:
- To review the structure and function of SPRY2 in RTK signaling.
- To explore the role of SPRY2 in brain-derived neurotrophic factor (BDNF) signaling pathways.
- To highlight the therapeutic potential of SPRY2 for neurological disorders.
Main Methods:
- Literature review of SPRY2 structure and interactions.
- Analysis of SPRY2's role in RTK and BDNF signaling pathways.
- Examination of SPRY2's involvement in neurodevelopmental disorders and therapeutic applications.
Main Results:
- SPRY2 inhibits RTK signaling by binding GRB2, preventing RAS activation and downstream ERK signaling.
- SPRY2's role in BDNF signaling is less understood but crucial for nervous system development.
- Increased SPRY2 levels are observed in neurological conditions, suggesting its involvement in disease pathology.
Conclusions:
- SPRY2 is a critical regulator of intracellular signaling with significant implications for neuronal function.
- Modulating SPRY2 activity presents a promising therapeutic strategy for neurological diseases.
- Further research into SPRY2's mechanisms can unlock novel treatments for neurodevelopmental disorders.
More Related Videos
05:28Author Spotlight: Unveiling the Molecular Basis of Pain Perception and Neuropathic Pain
Published on: August 9, 2024
09:32Light-mediated Reversible Modulation of the Mitogen-activated Protein Kinase Pathway during Cell Differentiation and Xenopus Embryonic Development
Published on: June 15, 2017
Related Concept Videos
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Cell Signaling in Plants
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Amplifying Signals via Enzymatic Cascade